Case Studies in Luminal Gastroenterology Adam Harris Consultant Gastroenterologist The Spire Tunbridge Wells Hospital
Dec 15, 2015
Case Studies in Luminal Gastroenterology
Adam Harris
Consultant Gastroenterologist
The Spire Tunbridge Wells Hospital
Luminal Gastroenterology
Learning objectives:
1. Avoiding foregut complications of NSAIDs
2. Understanding new dietary option in IBS
3. Understanding latest drug treatments in constipation
Case Study 1
87 yr old woman with OA, nocturnal joint pains, angina & bleeding DU 1999
Needs pain relief – what do you recommend?
NSAIDs & Bleeding ulcers
• PMH of ulcer bleeding who use NSAIDs are at highest risk (20%) of re-bleeding
• Use NSAID plus standard dose PPI
• Despite this 4-8% will re-bleed in 6 months
Chan et al. New Engl J Med 2002; 347:2104-10.
NSAIDs
High Risk of Complications• PMH PUD or bleed • >65 yrs • Longterm use; high dose • More than one NSAID• Co-prescribed steroids, clopidogrel or
warfarin• Serious co-morbidities
NSAIDs & PPIs
4 points to remember:1. PPIs decrease risk of NSAID-associated GU &
DU cf placebo2. PPIs equally effective whether non-selective
NSAIDs or COX-2 inhibitors3. PPI co-therapy is effective in healing &
preventing recurrent ulcers with long term NSAIDs
4. PPIs decrease risk of NSAID-associated bleeding
Aspirin 4 points to remember:
1. Aspirin increases risk of UGIB 4 fold
2. Aspirin + other NSAID increases risk 8 fold
3. No difference in RR with EC or “junior”
4. Eradication of H pylori decreases risk of ulcer
Lai et al. New Engl J Med 2002; 346: 2033-38
McQuaid KR, Laine L. Am J Med 2006; 119: 624-38
Arora G et al. Clin Gastro Hepatol 2009; 7: 725-35
Case Study 2 24 yr old female with 1-2 year of recurrent low abdominal pain, bloating & intermittent watery diarrhoea
Unemployed & lives alone
Normal examination
Blood tests, urine & stool culture normal
Faecal calprotectin <50
Low FODMAP diet
• Fermentable, Oligo-, Di-, Mono-saccharides and Polyols
• Comprise fructose, lactose, fructans, galactans & polyols
• Low FODMAP diet developed at Monash University in Melbourne, Australia
FODMAPs in diet
• Fructose eg fruits, honey, corn syrup• Lactose eg diary• Fructans eg wheat, onion, garlic• Galactans eg beans, lentils, legumes• Polyols eg sorbitol, avocado, apricots, plums
Low FODMAP
• FODMAP CHO trigger changes in fluid content & bacterial fermentation in bowel leading to symptoms in susceptible individuals
• Follow low FODMAP diet to eliminate fermentable carbohydrates; trained dietician required.
• Eliminate from diet for trial period then re-introduce each FODMAP carbohydrate gradually & record symptoms
• Reported (by enthusiasts) that up to 70% of patients report improvement in symptoms
Case Study 3
28 yr old woman with 5 yr history of constipation (BO 2 x/wk) with straining & passage of hard stool; bloating & low abdo discomfort
No incontinence. No neurological illness.
Examination & blood tests normal.
Tried fibre, lactulose, Movicol, Senna, bisacodyl with limited or no benefit.
Differential Diagnosis?
• IBS-C• Idiopathic Slow Transit Constipation• Functional Outlet Obstruction
Treatment Options
• IBS-C
linaclotide (Constella)
• ISTC
prucalopride (Resolor)
• Functional Outlet ObstructionFurther assessment; surgery; biofeedback
Prucalopride
• 5-HT4 receptor agonist with entero-colonic kinetic activity; not a laxative
• Women only• Works within 2-3 hours• ↑ spontaneous bowel movements: 67% vs
39% placebo (p<0.001)• Improves symptoms of pain, bloating,
straining & tenesmus
Prucalopride
• 2mg od for 28 days • If no response: do not continue• 1mg od: women>65 yr; liver/renal failure• AE: nausea; headache; abdo pain;
diarrhoea• Cost: 28 x 2mg ≈ £60
Linaclotide
• Guanylate cyclase-C agonist• Reduces visceral hypersensitivity, increases
intestinal secretion & accelerates transit• Treatment of moderate-severe IBS-C in adults• One capsule (290 mcg) od 30 mins before meal• Interaction: OCP, thyroxine• Adverse effect: diarrhoea (<20%)• Cost: £37.56 for 28 days
Linaclotide• 47% decrease in abdo pain over 26 weeks
(p<0.001 vs placebo)1
• 40% improvement in bloating over 26 weeks (p<0.0001 vs placebo)1
• Increase in spontaneous bowel movements from 1.7 to 5.7 weekly over 12 weeks (p<0.0001 vs placebo)2
• Improvement in QoL (p<0.01 vs placebo)
1. Quigley EM et al. Aliment Pharmacol Ther 2013; 37:49-61
2. Chey WD et al. Am J Gastroenterolo 2012; 107: 1702-12